Suppr超能文献

美国南部非城市地区未按预约就诊人群中丙型肝炎治疗障碍的定性研究。

A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.

机构信息

Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.

University of Virginia School of Medicine, Charlottesville, VA, USA.

出版信息

Harm Reduct J. 2020 Sep 18;17(1):64. doi: 10.1186/s12954-020-00409-9.

Abstract

BACKGROUND

Most people diagnosed with hepatitis C virus (HCV) have not linked to care, despite the availability of safe and effective treatment. We aimed to understand why people diagnosed with HCV have not pursued care in the non-urban Southern United States.

METHODS

We conducted a survey and semi-structured interview with participants referred to an HCV clinic who did not attend an appointment between 2014 and 2018. Our clinic is located in a non-urban region of Virginia at a university hospital. Qualitative data collection was guided by the Health Belief Model (HBM). Data was analyzed using qualitative content analysis to identify key factors influencing patient perceptions regarding HCV and pursuit of care.

RESULTS

Over half of previously referred patients (N = 200) could not be reached by phone. Eleven participants enrolled, including 7 men and 4 women. Based on survey responses, unreliable transportation, unstable housing, substance use, and lack of insurance were common. Participants demonstrated good knowledge of HCV disease, complications, and treatment. On qualitative analysis of semi-structured interviews, final themes emerged from within and between HBM constructs. Emerging themes influencing patient perceptions included (1) structural barriers, (2) stigma, (3) prior experiences of HCV disease and treatment, (4) discordance between the recognized severity of HCV and expected impacts on one's own health, and (5) patient-provider relationship. Substance use was not identified to be a barrier to care.

CONCLUSIONS

Participants perceived individual and structural barriers to linking to care. A strong HCV knowledge base was not sufficient to motivate pursuit of care. Efforts to improve linkage to care must address barriers at multiple levels, and system-level changes are needed. As the majority of previously referred patients could not be contacted by phone, current approaches to patient engagement are not effective for reaching these populations. Expansion of HCV care to primary care settings with an established patient-provider relationship or co-located treatment within substance use treatment programs may serve to increase access to HCV treatment.

摘要

背景

尽管已有安全有效的治疗方法,但大多数被诊断患有丙型肝炎病毒 (HCV) 的人并未寻求治疗。本研究旨在了解美国南部非城市地区为何有那么多被诊断患有 HCV 的人不寻求治疗。

方法

我们对 2014 年至 2018 年间未到 HCV 诊所就诊的患者进行了调查和半结构式访谈。我们的诊所位于弗吉尼亚州一个非城市地区的大学医院。定性数据收集以健康信念模型 (HBM) 为指导。使用定性内容分析来识别影响患者对 HCV 及其治疗的看法的关键因素,对数据进行分析。

结果

在之前转介的患者中,超过一半(N=200)无法通过电话联系到。有 11 名参与者入组,包括 7 名男性和 4 名女性。根据调查结果,交通不便、住房不稳定、药物滥用和缺乏保险是常见问题。参与者对 HCV 疾病、并发症和治疗方法有很好的了解。通过对半结构式访谈的定性分析,从 HBM 结构内和之间出现了一些主题。影响患者看法的主题包括:(1)结构性障碍,(2)污名,(3)对 HCV 疾病和治疗的先前经历,(4)HCV 严重程度的公认程度与对自身健康影响的预期之间的差异,以及(5)医患关系。药物滥用未被确定为寻求治疗的障碍。

结论

参与者认为存在个体和结构性障碍,无法寻求治疗。对 HCV 的深入了解不足以激发他们寻求治疗。必须在多个层面上努力解决阻碍治疗的问题,需要进行系统层面的变革。由于大多数之前转介的患者无法通过电话联系,目前的患者参与方法对这些人群效果不佳。将 HCV 护理扩展到有患者-医生关系的初级保健机构或在药物滥用治疗项目中提供治疗,可能有助于增加 HCV 治疗的可及性。

相似文献

6
Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice.
J Viral Hepat. 2020 May;27(5):484-496. doi: 10.1111/jvh.13259. Epub 2020 Feb 3.
8
'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
Drug Alcohol Depend. 2018 Sep 1;190:246-254. doi: 10.1016/j.drugalcdep.2018.06.013. Epub 2018 Jul 20.
10
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma.
J Subst Abuse Treat. 2022 Jun;137:108684. doi: 10.1016/j.jsat.2021.108684. Epub 2021 Dec 7.

引用本文的文献

1
Hepatitis C Care in the Greater New Orleans Area: Patient Perspectives on the Barriers and Facilitators to Care.
J Health Care Poor Underserved. 2025;36(1):257-283. doi: 10.1353/hpu.2025.a951596.
2
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.
PLOS Glob Public Health. 2025 Jan 16;5(1):e0003284. doi: 10.1371/journal.pgph.0003284. eCollection 2025.
3
Medicaid Policy and Hepatitis C Treatment Among Rural People Who Use Drugs.
Med Care. 2025 Feb 1;63(2):77-88. doi: 10.1097/MLR.0000000000002095. Epub 2024 Nov 18.
4
Slicing through silos: Development and evaluation of a hospital-based telehealth hepatitis C virus treatment program.
Int J Drug Policy. 2024 May;127:104396. doi: 10.1016/j.drugpo.2024.104396. Epub 2024 Apr 9.
6
Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject Drugs.
J Gen Intern Med. 2023 Nov;38(15):3428-3433. doi: 10.1007/s11606-023-08386-y. Epub 2023 Aug 31.
8
Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.
J Gen Intern Med. 2022 Oct;37(13):3435-3443. doi: 10.1007/s11606-022-07628-9. Epub 2022 Apr 28.
9
Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
PLoS One. 2022 Mar 23;17(3):e0265811. doi: 10.1371/journal.pone.0265811. eCollection 2022.
10
Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders.
BMC Public Health. 2022 Feb 21;22(1):371. doi: 10.1186/s12889-022-12786-w.

本文引用的文献

4
Rural risk environments for hepatitis c among young adults in appalachian kentucky.
Int J Drug Policy. 2019 Oct;72:47-54. doi: 10.1016/j.drugpo.2019.05.006. Epub 2019 May 18.
5
Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
Int J Drug Policy. 2019 Oct;72:138-145. doi: 10.1016/j.drugpo.2019.03.015. Epub 2019 Apr 15.
7
Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016.
JAMA Netw Open. 2018 Dec 7;1(8):e186371. doi: 10.1001/jamanetworkopen.2018.6371.
9
The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.
J Viral Hepat. 2018 Nov;25 Suppl 3:6-14. doi: 10.1111/jvh.13005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验